Compare TFX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFX | GRFS |
|---|---|---|
| Founded | 1943 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.2B |
| IPO Year | 1994 | N/A |
| Metric | TFX | GRFS |
|---|---|---|
| Price | $132.16 | $8.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $138.75 | $10.15 |
| AVG Volume (30 Days) | 389.7K | ★ 723.1K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | 1.02% | ★ 1.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,992,713,000.00 | N/A |
| Revenue This Year | $15.97 | $4.49 |
| Revenue Next Year | $5.15 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $100.18 | $6.96 |
| 52 Week High | $139.67 | $10.88 |
| Indicator | TFX | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 67.64 |
| Support Level | $126.25 | $7.76 |
| Resistance Level | $137.19 | $8.35 |
| Average True Range (ATR) | 3.81 | 0.17 |
| MACD | -0.12 | 0.10 |
| Stochastic Oscillator | 59.45 | 91.54 |
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.